Lopez would be happy there was plenty of discussion on a Nasdaq...

Lopez would be happy there was plenty of discussion on a Nasdaq listing. Doesn't mean they will do it but it appears it is a discussion point.

A top ten shareholder was there and gave the opinion it should be done in his view. I was hoping to chat to him but perhaps next year.

They will not elaborate at all on discussions with big pharma. They only restated lots of interest during the year at conferences. As you can see on the preso they stressed the amount of pharma wanting to play in that space. They did say they had a podium at SITC.

The fact is they can't push big pharma for that crystallisation event.

Lot of discussion on the share price and desire to be higher.

Recruiting of trials seems to be going well.

Big concern is cash burn rate with there current balance, so the question is can they get part funding on a future trial.

These were my personal take always and shouldn't be relied on for investment decisions. They are very subjective and I have personal bias.